Related Experiment Video
Updated: May 3, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Metastatic renal cell carcinoma: Current scenario and future trends
1Department of Medical Oncology and Hematology, Patel Cancer and Superspeciality Hospital, Jalandhar City, Punjab, India.
Abstract:
An improved understanding of the biology of renal cell carcinoma (RCC) has led to the development of a number of targeted agents, which has resulted in a paradigm shift in the management of metastatic RCC. We review the current therapeutic strategies for metastatic RCC and present a synopsis of the novel agents in use today with a discussion of the phase III trials that demonstrated their clinical benefit. The management of RCC continues to evolve. The introduction of VEGF and mTOR inhibitors has markedly expanded our drug armamentarium and improved the outcome of a disease that has always been challenging to treat. Knowledge from upcoming trials will help us utilize these drugs for maximum clinical efficacy with optimal dosing and sequencing, either individually or in combination therapy.
Insights
Targeted therapies, including VEGF and mTOR inhibitors, have transformed metastatic renal cell carcinoma (RCC) treatment. Ongoing research will optimize the use of these agents for improved patient outcomes.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic renal cell carcinoma (RCC) management has been historically challenging.
- Advances in understanding RCC biology have paved the way for novel targeted therapies.
Purpose of the Study:
- To review current therapeutic strategies for metastatic RCC.
- To present a synopsis of novel agents and discuss their clinical benefit demonstrated in phase III trials.
Main Methods:
- Review of current literature and phase III clinical trial data for targeted agents in metastatic RCC.
- Analysis of the impact of VEGF and mTOR inhibitors on treatment outcomes.
Main Results:
- The introduction of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors has significantly expanded treatment options.
- These targeted agents have markedly improved outcomes for patients with metastatic RCC.
Conclusions:
- The management of metastatic RCC has shifted paradigms due to targeted therapies.
- Future trials will guide optimal dosing, sequencing, and combination strategies for maximal clinical efficacy.
More Related Videos
Related Concept Videos
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
03:03mTOR Signaling and Cancer Progression
02:56Treatment Resistent Cancers